Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of 22.54 billion. The enterprise value is 27.38 billion.
Important Dates
The next estimated earnings date is Tuesday, October 29, 2024.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.06% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.73B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.13 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 14.02, with an EV/FCF ratio of 33.66.
| EV / Earnings | 204.71 |
| EV / Sales | 2.29 |
| EV / EBITDA | 14.02 |
| EV / EBIT | 41.83 |
| EV / FCF | 33.66 |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 59.21.
| Current Ratio | 0.90 |
| Quick Ratio | 0.66 |
| Debt / Equity | 59.21 |
| Debt / EBITDA | 3.55 |
| Debt / FCF | 7.58 |
| Interest Coverage | 6.90 |
Financial Efficiency
Return on equity (ROE) is 1.32% and return on invested capital (ROIC) is 2.58%.
| Return on Equity (ROE) | 1.32% |
| Return on Assets (ROA) | 1.82% |
| Return on Capital (ROIC) | 2.58% |
| Revenue Per Employee | 717,028 |
| Profits Per Employee | 9,067 |
| Employee Count | 14,754 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.64% in the last 52 weeks. The beta is 0.29, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -15.64% |
| 50-Day Moving Average | 11.41 |
| 200-Day Moving Average | 10.90 |
| Relative Strength Index (RSI) | 62.53 |
| Average Volume (20 Days) | 64,394 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of 10.58 billion and earned 133.77 million in profits. Earnings per share was 0.07.
| Revenue | 10.58B |
| Gross Profit | 8.62B |
| Operating Income | 591.33M |
| Pretax Income | 177.87M |
| Net Income | 133.77M |
| EBITDA | 1.74B |
| EBIT | 591.33M |
| Earnings Per Share (EPS) | 0.07 |
Full Income StatementBalance Sheet
The company has 1.88 billion in cash and 6.17 billion in debt, giving a net cash position of -4.29 billion.
| Cash & Cash Equivalents | 1.88B |
| Total Debt | 6.17B |
| Net Cash | -4.29B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 10.42B |
| Book Value Per Share | 5.82 |
| Working Capital | -827.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 1.07 billion and capital expenditures -261.03 million, giving a free cash flow of 813.63 million.
| Operating Cash Flow | 1.07B |
| Capital Expenditures | -261.03M |
| Free Cash Flow | 813.63M |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 81.51%, with operating and profit margins of 5.59% and 1.26%.
| Gross Margin | 81.51% |
| Operating Margin | 5.59% |
| Pretax Margin | 1.68% |
| Profit Margin | 1.26% |
| EBITDA Margin | 16.45% |
| EBIT Margin | 5.59% |
| FCF Margin | 7.69% |